rethinkPeptides Search
Menu
Study breakdown

Self-Reinforcing CGRP Feedback Loop Discovered as Driver of Chronic Migraine

evidence
The takeaway

A positive feedback loop involving CREB, KIF1A, and the peptide CGRP drives chronic migraine by keeping CGRP production and signaling perpetually activated.

Positive feedback loop identified

CREB activates KIF1A, which promotes CGRP production, and CGRP signals back to reactivate CREB — creating a self-sustaining cycle that explains why chronic migraine persists.

What the researchers found

Researchers discovered a self-reinforcing feedback loop — CREB→KIF1A→CGRP→CREB — that drives chronic migraine. CREB directly activates transcription of KIF1A (a motor protein), which physically associates with CGRP and promotes its transport and expression. CGRP signaling then feeds back to reactivate CREB, creating a positive loop. Disrupting any component of this axis — inhibiting CREB, knocking down KIF1A, or blocking the CGRP receptor — effectively reduced migraine-like pain behaviors and molecular markers of central sensitization in mice.

Why it matters

While CGRP is a proven migraine target, why it stays elevated in chronic migraine has been unclear. This study explains the mechanism: a feedback loop keeps CGRP production running. Understanding this loop reveals new upstream targets (CREB, KIF1A) that could be blocked to treat chronic migraine, potentially offering alternatives for patients who don't respond to anti-CGRP antibodies. It also explains how episodic migraine may become chronic through self-sustaining CGRP signaling.

The numbers in context

NTG-induced chronic migraine model · CREB directly binds Kif1a promoter (ChIP/luciferase confirmed) · KIF1A physically associates with CGRP (Co-IP confirmed) · Kif1a knockdown reduced CGRP in synaptic vesicles · CGRP receptor blockade inhibited CREB/KIF1A activation

How the study worked

Chronic migraine was modeled in mice using repeated nitroglycerin injections. Researchers used behavioral testing (thermal/mechanical allodynia), molecular analyses (immunoblotting, qPCR, immunofluorescence), ChIP and dual-luciferase assays (to confirm CREB binds Kif1a promoter), co-immunoprecipitation (KIF1A-CGRP interaction), synaptosomal analysis (vesicle CGRP levels), and pharmacological interventions (Forskolin/CREB agonist, 666-15/CREB inhibitor, Kif1a knockdown/overexpression, Olcegepant/CGRP receptor antagonist).

Who was studied

C57BL/6 mice in nitroglycerin-induced chronic migraine model and Neuro-2a cell cultures

What this study cannot tell us

This is a mouse model study using nitroglycerin-induced migraine, which may not fully recapitulate human chronic migraine. The interventions (gene knockdown, CREB inhibitors) are not yet available as clinical treatments. The feedback loop was characterized primarily in spinal trigeminal neurons and Neuro-2a cells, and additional brain regions involved in migraine were not examined.

How to read the evidence

This is a rigorous preclinical mechanistic study using multiple complementary approaches (genetic, pharmacological, biochemical) that converge on the same conclusion. The evidence for the feedback loop mechanism is strong, but validation in human tissue and clinical relevance requires further study.

When this study was published

Published in 2025, this study represents cutting-edge research into the molecular mechanisms underlying chronic migraine and CGRP regulation.

The bigger picture

This study provides a mechanistic explanation for migraine chronification — how occasional migraines become frequent, disabling chronic migraines. The discovery of an upstream regulatory loop controlling CGRP could explain why some patients don't respond to anti-CGRP antibodies (the loop may maintain sensitization through other pathways) and suggests that combination approaches targeting multiple loop components could be more effective than CGRP blockade alone.

Questions still open

  • Could targeting CREB or KIF1A help patients who don't respond to anti-CGRP monoclonal antibodies?
  • Is this feedback loop active in human chronic migraine patients, and could it be measured as a biomarker?
  • Does the CREB-KIF1A-CGRP loop also operate in other pain conditions involving CGRP, such as cluster headache?

Common questions

Why does this feedback loop matter for people with chronic migraine?
Chronic migraine affects about 2% of the global population and is much harder to treat than occasional migraines. This feedback loop explains why: once it's activated, CGRP production becomes self-sustaining. Even if you block CGRP with antibodies, the upstream components (CREB, KIF1A) keep trying to produce more. Understanding this cycle reveals additional drug targets that could be blocked to more effectively treat chronic migraine.
What is KIF1A and why is it involved in migraine?
KIF1A is a molecular motor protein that transports cargo along nerve cell axons. In this context, it physically associates with CGRP and helps transport it within nerve cells. When KIF1A levels increase (driven by CREB), more CGRP is produced and transported, amplifying pain signaling. This is a completely new discovery connecting the cellular transport machinery to migraine pathophysiology.

Read the original research

CREB-KIF1A-CGRP-positive feedback loop drives central sensitization in chronic migraine.

The journal of headache and pain, 26(1), 194

Citation

Jiang, Wei; Yu, Peng; Shi, Yan-Min; Zhang, Li-Xi; Cai, Meng-Tan; Yang, Yu; Dong, Ming. (2025). CREB-KIF1A-CGRP-positive feedback loop drives central sensitization in chronic migraine.. The journal of headache and pain, 26(1), 194. https://doi.org/10.1186/s10194-025-02147-4